Latest Conference Coverage

Episode 117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Anthony Feinstein, PhD, FRCPC, MBBCh; Brian G. Weinshenker, MD; Douglas A. Wajda, PhD; Le Hua, MD; and Eoin P. Flanagan, MB, BCh. [LISTEN TIME: 22 minutes]

Promising Developments in Pharmaceutical Treatments for Sleep Apnea: Sanjay R. Patel, MD, MS

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]

Using the Cionic Neural Sleeve to Alleviate Gait Dysfunction in Multiple Sclerosis: Douglas A. Wajda, PhD

The assistant professor of neurology at Cleveland State University provided perspective on an early-stage study assessing the impacts of a functional electrical stimulation approach to treat gait problems in multiple sclerosis. [WATCH TIME: 4 minutes]

Closing the Gaps in Underserved Multiple Sclerosis Communities: Yahaira Rivera, MBEd

The director of Mission Delivery and Program Development for the Multiple Sclerosis Association of America provided perspective on a study presented at CMSC 2024 highlighting factors that play a role in access to resources and healthcare for patients with MS. [WATCH TIME: 3 minutes]

Using Social Listening Analyses to Better Characterize Patient Experiences With Narcolepsy: Anne Marie Morse, DO, FAASM

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center discussed a presentation from SLEEP 2024 highlighting the impacts of narcolepsy and how patients try to mitigate their symptoms. [WATCH TIME: 5 minutes]

NeuroVoices: William L. Conte, MD, MS, on Improving Care for LGBTQ+ Patients With Multiple Sclerosis

The head of the MS Center at Methodist Hospitals discussed the need for inclusive and affirming healthcare practices for patients with multiple sclerosis who identify as LGBTQ+.

Updates in the Diagnosis and Management of Primary Progressive Multiple Sclerosis: Patricia K. Coyle, MD

The professor of neurology at Stony Brook Medicine talked about the diagnosis of primary progressive multiple sclerosis, a unique MS phenotype characterized by a gradual deterioration without initial attack. [WATCH TIME: 5 minutes]

Localization and Puzzling Together the Bigger Picture in Multiple Sclerosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

The assistant professor at Hunter College emphasized the important role of localization and accurately identifying the origin of neurological symptoms when diagnosing and managing multiple sclerosis. [WATCH TIME: 7 minutes]

The Clinical Pearls for Diagnosing and Treating NMOSD: Brian G. Weinshenker, MD, FRCP

The professor of neurology at the University of Virginia talked about the improvement and areas of unmet need in the diagnosis and treatment for neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]

Diagnostic Code Aids in Predicting Isolated REM Sleep Behavior Disorder in Outpatient Setting

A recent study showed that patients with isolated REM sleep behavior disorder had a high risk of neurodegenerative parkinsonian disorders or dementia based on electronic health records.

The Importance of Early Referral and Interdisciplinary Care in MS: Kathy Zackowski, PhD, OTR

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]

Deep Learning Model Predicts Cognitive Status With High Accuracy From Sleep EEG Data

Researchers presented an innovative multi-task learning paradigm that leveraged deep learning, night sleep EEG data, sleep stage labels, and covariates to simultaneously predict cognitive performance in an older patient cohort.

Pooled Phase 3 Data Suggests 50 mg Daridorexant as Most Effective Starting Dose in Insomnia

Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.

Qualitative Interviews Reveal Impact of Fatigue and Sleepiness in Obstructive Sleep Apnea

A recent study showed that patients with obstructive sleep apnea experience significant negative impacts on their physical, social, and emotional functioning.

NeuroVoices: James Rowley, MD, on SLEEP 2024 and the Direction of the AASM

The pulmonologist at Rush Health and immediate past president of the American Academy of Sleep Medicine provided perspective on some of the intriguing changes to sleep medicine and where the field is headed in the coming years.

Obstructive Sleep Apnea Status Affects Glymphatic System Function and Cognitive Function

A recent study showed that obstructive sleep apnea may impact the long-term disruption of the glymphatic system function and the development of neurodegenerative diseases.

Doxepin Demonstrates Effectiveness to Treat Sleep Latency in Insomnia

Assessing doses of 3 mg doxepin, results revealed non-statistically significant improvements in latency to sleep onset and latency to persistent sleep that were observed across patients above and at or below the median baseline values.

Age-Dependent Risk for Neurodegenerative Disorder Identified in Obstructive Sleep Apnea

In a clinical cohort study, approximately 89% of patients with obstructive sleep apnea classified as “Probably-normal” or “Likely-normal" in assessment of sleep biomarker-based neurodegenerative disorder risk.

Understanding the Role of Sleep in the Emergence of Neurodevelopmental Disorders: Temitayo Oyegbile-Chidi, MD, PhD

The pediatric neurologist at the University of California, Davis, provided perspective on some of the mechanistic links between sleep and neurodevelopmental disorders. [WATCH TIME: 3 minutes]

SynAIRgy Phase 3 Trial Aims to Assess Pharmacological Activation of Upper Airway Muscles to Treat Obstructive Sleep Apnea

A phase 3 trial plans to investigate the efficacy and safety of AD109, a novel oral medication, for treating obstructive sleep apnea in patients who cannot tolerate continuous positive airway pressure therapy.

Adverse Events of Low-Sodium Oxybate in Idiopathic Hypersomnia Begin Early in Treatment Course

Regardless of whether patients were treatment-naïve or taking alerting agents, the safety profile of low-sodium oxybate remained true, with treatment-emergent adverse events attributing to less than 4% of study discontinuations.

Cognitive Behavioral Therapy for Insomnia Shows Promise in Pilot Trial of Epilepsy

Overall, most patients reported satisfaction with cognitive behavioral therapy approach, with completion of lessons associated with a decrease in Fatigue Severity Scale.

Emerging Treatment Approaches and Medical Devices for Obstructive Sleep Apnea: Kin Yuen, MD, MS

The sleep medicine specialist at the University of California, San Francisco provided perspective on some of the innovative therapeutic strategies in development for patients with obstructive sleep apnea. [WATCH TIME: 5 minutes]

Study Highlights Sleep Challenges and Self-Help Strategies for Pediatric Epilepsy

A recent study demonstrated no significant difference in sleep efficiency between pediatric patients with epilepsy who used self-help strategies for sleep aids and those who did not.

Depression Associated With Increased Risk of Neurodegenerative Diseases in Isolated REM Sleep Behavior Disorder

A recent study presented at SLEEP 2024 showed that depression in patients with isolated REM sleep behavior disorder significantly increased the risk of conversion to neurodegenerative diseases.

Low-Sodium Oxybate Remains Effective, Safe in Narcolepsy With Psychiatric and Neurologic Comorbidities

Those on low-sodium oxybate, regardless of psychiatric comorbidity status, outperformed placebo on a number of outcomes, including Epworth Sleepiness Scale and weekly cataplexy attacks.

Early Report Suggest Disease-Modifying Therapies May Halt Sleep-Related Disordered Breathing in Spinal Muscular Atrophy

A majority of the small cohort of patients with SMA did not need a polysomnogram at 1 year because respiratory pathology was not a concern, attributable to improvements from disease-modifying therapies.

The Complexity of Immune Cell Interactions and Potential Treatments for MS: Jenn Orthmann-Murphy, MD, PhD

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania talked about her presentation at CMSC 2024 on the complex interactions of immune cells in multiple sclerosis. [WATCH TIME: 6 minutes]

KP1077 Shows Promise as Potential Treatment for Idiopathic Insomnia in Phase 2 Trial

After 5 weeks of open-label treatment, KP1077-treated patients showed mild adverse events that were typical for a central nervous system stimulant.

Recognizing the Clinical Features of MOGAD for Diagnosis: Eoin P. Flanagan, MB, BCh

The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]